San Diego, CA (PRWEB) April 05, 2013
The medication resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. Researchers warned this month that use of the drug may make patients more prone to viral infections****.
DrugRisks was created to reduce the danger of side effects from popular prescription drugs by providing patients with the latest warnings, recalls, studies and legal news. Visitors can discuss side effect concerns with their doctor and decide if they need legal advice.
Health experts have disagreed about whether Pradaxa is associated with higher risks for internal bleeding. The FDA has updated its information to state the drug is as safe as warfarin*. However, the Institute for Safe Medication Practices recently ranked these blood thinners among the most dangerous drugs available and warned that patients with bleeding from Pradaxa were nearly 5 times as likely to die than those with warfarin bleeding**.
DrugRisks has also added a study from the University of Illinois at Chicago which showed the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than previously thought***.
In the latest news added to DrugRisks, researchers at the University of North Carolina have discovered that the blood-thinning properties of Pradaxa may also make patients more susceptible to certain viral infections such as flu and myocarditis****.
The resource center has learned that due to the number of patients who have filed a Pradaxa lawsuit over allegations of internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. Since federal drug injury cases can be very specialized, DrugRisks only recommends lawyers who have already handled Pradaxa lawsuits.
**Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf